PMID- 23822993
OWN - NLM
STAT- MEDLINE
DCOM- 20140311
LR  - 20220309
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 209
IP  - 8
DP  - 2013 Aug
TI  - Significance of TFF3 protein and Her-2/neu status in patients with gastric 
      adenocarcinoma.
PG  - 479-85
LID - S0344-0338(13)00115-5 [pii]
LID - 10.1016/j.prp.2013.04.017 [doi]
AB  - Increased knowledge of molecular alterations involved in gastric carcinogenesis 
      has provided useful information for diagnosis and prediction. In this study, we 
      investigated the clinicopathological significance of TFF3 expression and 
      Her-2/neu status in gastric adenocarcinoma and explored the correlation between 
      TFF3 expression and Her-2/neu status. A hundred and twenty-six (126) patients 
      having undergone curative gastrectomy were enrolled. Immunohistochemistry for 
      TFF3 was performed on tumor tissues and non-neoplastic resection margins. 
      Her-2/neu status was assessed by immunohistochemical staining and fluorescence in 
      situ hybridization (FISH) on tumor tissues. As a result, TFF3 expression and 
      Her-2/neu positivity were detected in 46.8% and 11.9% of the cases, respectively. 
      Patients with negative TFF3 exhibited longer survival than the positive group 
      (P=0.0142), while patients with positive Her-2/neu only showed a tendency toward 
      longer overall survival (P>0.05). However, Her-2/neu was significantly associated 
      with improved disease-free survival (P=0.0234). Multivariate analysis 
      demonstrated Her-2/neu and TFF3 to be independent prognostic indicators of 
      recurrence, and a significantly poor prognosis for expression of TFF3 in patients 
      with Her-2/neu negative tumors. TFF3 is an independent indicator for overall 
      survival in gastric cancer, while Her-2/neu, as a marker of long time survival 
      prediction, seems to be limited.
CI  - Copyright (c) 2013 Elsevier GmbH. All rights reserved.
FAU - Xu, Cong-cong
AU  - Xu CC
AD  - Department of Oncology, The Affiliated Hospital of Medical College, Qingdao 
      University, 16 Jiangsu Road, Qingdao 266003, China.
FAU - Yue, Lu
AU  - Yue L
FAU - Wei, Hong-jun
AU  - Wei HJ
FAU - Zhao, Wen-wen
AU  - Zhao WW
FAU - Sui, Ai-hua
AU  - Sui AH
FAU - Wang, Xiu-mei
AU  - Wang XM
FAU - Qiu, Wen-sheng
AU  - Qiu WS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130607
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Peptides)
RN  - 0 (TFF3 protein, human)
RN  - 0 (Trefoil Factor-3)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/*chemistry/*genetics/mortality/pathology/surgery
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Chi-Square Distribution
MH  - Disease-Free Survival
MH  - Female
MH  - Gastrectomy
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Peptides/*analysis
MH  - Proportional Hazards Models
MH  - Receptor, ErbB-2/*analysis/genetics
MH  - Risk Factors
MH  - Stomach Neoplasms/*chemistry/*genetics/mortality/pathology/surgery
MH  - Time Factors
MH  - Treatment Outcome
MH  - Trefoil Factor-3
OTO - NOTNLM
OT  - Gastric cancer
OT  - Her-2/neu
OT  - Prognosis
OT  - TFF3
EDAT- 2013/07/05 06:00
MHDA- 2014/03/13 06:00
CRDT- 2013/07/05 06:00
PHST- 2012/12/15 00:00 [received]
PHST- 2013/04/22 00:00 [revised]
PHST- 2013/04/25 00:00 [accepted]
PHST- 2013/07/05 06:00 [entrez]
PHST- 2013/07/05 06:00 [pubmed]
PHST- 2014/03/13 06:00 [medline]
AID - S0344-0338(13)00115-5 [pii]
AID - 10.1016/j.prp.2013.04.017 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2013 Aug;209(8):479-85. doi: 10.1016/j.prp.2013.04.017. Epub 
      2013 Jun 7.